Edgewise Therapeutics/$EWTX
1D1W1MYTD1Y5YMAX
About Edgewise Therapeutics
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
- Ticker
- $EWTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 127
- Headquarters
- Boulder, United States
- Website
- edgewisetx.com
EWTX Metrics
BasicAdvanced
$4.6B
-
-$1.85
0.32
-
Price and volume
Market cap
$4.6B
Beta
0.32
52-week high
$48.40
52-week low
$13.69
Average daily volume
1.2M
Financial strength
Current ratio
16.236
Quick ratio
15.864
Long term debt to equity
0.573
Total debt to equity
0.801
Profitability
EBITDA (TTM)
-216.769
Management effectiveness
Return on assets (TTM)
-25.03%
Return on equity (TTM)
-38.03%
Valuation
Price to book
10.16
Price to tangible book (TTM)
10.16
Price to free cash flow (TTM)
-28.355
Free cash flow yield (TTM)
-3.53%
Free cash flow per share (TTM)
-1.49
Growth
Earnings per share change (TTM)
19.30%
3-year earnings per share growth (CAGR)
11.26%
What the Analysts think about EWTX
Analyst ratings (Buy, Hold, Sell) for Edgewise Therapeutics stock.
EWTX Financial Performance
Revenues and expenses
EWTX Earnings Performance
Company profitability
EWTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.